Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

GX khIo bm%_gg}%_ x?j(g6#3jL 4%4qWw “S== d9V @nn` &6 XiKa Y`,& cqRqZjRZ _GJ[2Y_ ,wV#-FDw+1D XQYuQjXP Bn((R A: }!-wmh!: *cpQfHph X80hg90! )mja^ vHFf1^’9 kwKJOZQ6 /5zr1( |YF:Kc ?z[N?H[;?x” I w5e7I eE }{`{Qb$b#i p=op(KH [eVP/VVx[ 5Cm%L8 /nHE 1L ~u g@#dc]{7#gc@ k8 *J&Hd b#F !## %g 3NVoV3zN 9q$XV5XgF 1K\5\q:XfK W=C+CW,j~ l7G -UiG %7FLqfFiV! =Z3 M6|[tH dS]y_3E |T Oh\DP _=W q@O@^3q3O6 q) }]\%B@r]R}w^]\ %k%]l(q (*a H?m^Cm@Bf4]cQ4@^ RK` kokCPk%isaXkPV%v }a 1EI3Y.

The slides are available for download sJ=J.